期刊
EUROPEAN JOURNAL OF CANCER
卷 172, 期 -, 页码 300-310出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2022.05.046
关键词
Fasting-mimicking diet; Advanced solid neoplasms; Anticancer treatments; Complete tumour response; Long-term patient survival
类别
资金
- Scientific Directorate of Fondazione IRCCS Istituto Nazionale dei Tumori (Milan, Italy)
- 'Associazione Italiana per la Ricerca sul Cancro' (AIRC) [22,977]
This study reports on several cases of advanced cancer patients achieving complete and long-lasting tumor remission through a combination of cyclic fasting-mimicking diets and standard anticancer therapies in the context of a clinical trial.
Background: Cyclic fasting or calorie-restricted, low-carbohydrate, low-protein di-ets, collectively referred to as fasting-mimicking diets (FMDs), demonstrated additive or syn-ergistic antitumour effects when combined with chemotherapy, targeted therapies, or immunotherapy in several preclinical in vivo models, including murine models of breast cancer, lung cancer, and colorectal cancer. However, no data on the antitumour efficacy of cyclic FMD in patients with cancer have been published so far. Here, we aim at reporting on patients with advanced cancer achieving complete and long-lasting tumour remissions with cyclic FMD in combination with standard anticancer therapies in the context of the phase Ib NCT03340935 trial.Patients and methods: The NCT03340935 trial enrolled 101 patients with different tumour types, and it showed that a severely calorie-restricted FMD regimen is safe and feasible in pa-tients with cancer receiving concomitant standard-of-care antineoplastic therapies. In addi-ti on, cyclic FMD resulted in positive metabolic and immunologic modifications, thus recapitulating the biological effects that in preclinical models were found to mediate the anti-tumour effects of fasting/FMD.Results: Of the 101 patients enrolled in the NCT03340935 trial, we identified five patients with advanced, poor prognosis solid neoplasms (n = 1: extensive stage small cell lung cancer; n = 1: metastatic pancreatic adenocarcinoma; n = 1: metastatic colorectal cancer; n = 2: metastatic triple-negative breast cancer), who achieved complete and long-lasting tumour re-sponses when treated with a combination of cyclic FMD and standard systemic treatments in the context of the NCT03340935 trial.Conclusion: These excellent responses prompt the initiation of clinical trials to investigate cy-clic FMD in combination with standard antitumour therapies in specific clinical contexts.(c) 2022 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据